CCG 203971CAS# 1443437-74-8 |
- JNK-IN-7
Catalog No.:BCC1672
CAS No.:1408064-71-0
- JNK-IN-8
Catalog No.:BCC1673
CAS No.:1410880-22-6
- CC-401 hydrochloride
Catalog No.:BCC1458
CAS No.:1438391-30-0
- AS 602801
Catalog No.:BCC1369
CAS No.:848344-36-5
- DB07268
Catalog No.:BCC1519
CAS No.:929007-72-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1443437-74-8 | SDF | Download SDF |
| PubChem ID | 71681561 | Appearance | Powder |
| Formula | C23H21ClN2O3 | M.Wt | 408.88 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 155 mg/mL (379.08 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | N-(4-chlorophenyl)-1-[3-(furan-2-yl)benzoyl]piperidine-3-carboxamide | ||
| SMILES | C1CC(CN(C1)C(=O)C2=CC=CC(=C2)C3=CC=CO3)C(=O)NC4=CC=C(C=C4)Cl | ||
| Standard InChIKey | HERLZBNILRVHQN-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C23H21ClN2O3/c24-19-8-10-20(11-9-19)25-22(27)18-6-2-12-26(15-18)23(28)17-5-1-4-16(14-17)21-7-3-13-29-21/h1,3-5,7-11,13-14,18H,2,6,12,15H2,(H,25,27) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Antifibrotic agent; inhibits fibrosis by targeting the MRTF/SRF gene transcription pathway. Selectively inhibits proliferation of SSc-derived dermal fibroblasts but not that of normal fibroblasts. Inhibits expression of CTGF, α-SMA, and COL1A2 in SSc fibroblasts as well as in LPA and in TGFβ-stimulated fibroblasts. Prevents bleomycin-induced skin thickening and collagen deposition in vivo. Also suppresses PC-3 cell migration in scratch wound assays (IC50 = 4.2 μM). |
CCG 203971 Dilution Calculator
CCG 203971 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4457 mL | 12.2285 mL | 24.4571 mL | 48.9141 mL | 61.1426 mL |
| 5 mM | 0.4891 mL | 2.4457 mL | 4.8914 mL | 9.7828 mL | 12.2285 mL |
| 10 mM | 0.2446 mL | 1.2229 mL | 2.4457 mL | 4.8914 mL | 6.1143 mL |
| 50 mM | 0.0489 mL | 0.2446 mL | 0.4891 mL | 0.9783 mL | 1.2229 mL |
| 100 mM | 0.0245 mL | 0.1223 mL | 0.2446 mL | 0.4891 mL | 0.6114 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Nemoralisin C
Catalog No.:BCN7680
CAS No.:1443421-84-8
- YM 26734
Catalog No.:BCC7396
CAS No.:144337-18-8
- Trilepisflavan
Catalog No.:BCN6786
CAS No.:1443218-16-3
- 1-Deazaadenosine
Catalog No.:BCC6204
CAS No.:14432-09-8
- ML 337
Catalog No.:BCC6345
CAS No.:1443118-44-2
- Dehydroadynerigenin glucosyldigitaloside
Catalog No.:BCN1568
CAS No.:144223-70-1
- YYA-021
Catalog No.:BCC5346
CAS No.:144217-65-2
- 1-Acetyl-4-methylpiperazine hydrochloride
Catalog No.:BCC6615
CAS No.:144205-68-5
- Indoxacarb
Catalog No.:BCN2263
CAS No.:144171-61-9
- Ledipasvir acetone
Catalog No.:BCC4046
CAS No.:1441674-54-9
- Eprosartan Mesylate
Catalog No.:BCC4658
CAS No.:144143-96-4
- Fmoc-Glu-OAll
Catalog No.:BCC3490
CAS No.:144120-54-7
- GSK2838232
Catalog No.:BCC6372
CAS No.:1443461-21-9
- 8-(7-Hydroxy-3,7-dimethyl-2,5-octadienyloxy)psoralen
Catalog No.:BCN1567
CAS No.:144398-34-5
- 3-Oxopomolic acid methyl ester
Catalog No.:BCN3723
CAS No.:14440-23-4
- Canophyllal
Catalog No.:BCN7441
CAS No.:14440-40-5
- 3-O-(E)-p-Coumaroylbetulin
Catalog No.:BCN6247
CAS No.:144424-80-6
- Aflavarin
Catalog No.:BCN7410
CAS No.:144429-67-4
- Goniodiol 8-acetate
Catalog No.:BCN4787
CAS No.:144429-71-0
- Beta-Aflatrem
Catalog No.:BCN6699
CAS No.:144446-23-1
- Clopidogrel Related Compound A
Catalog No.:BCN2687
CAS No.:144457-28-3
- Tirofiban
Catalog No.:BCC4868
CAS No.:144494-65-5
- Licochalcone C
Catalog No.:BCN6334
CAS No.:144506-14-9
- Rotundatin
Catalog No.:BCN7856
CAS No.:144506-16-1
Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma.[Pubmed:28285914]
Bioorg Med Chem Lett. 2017 Apr 15;27(8):1744-1749.
We recently reported the development of a novel inhibitor of Rho-mediated gene transcription (1, CCG-203971) that is efficacious in multiple animal models of acute fibrosis, including scleroderma, when given intraperitoneally. The modest in vivo potency and poor pharmacokinetics (PK) of this lead, however, make it unsuitable for long term efficacy studies. We therefore undertook a systematic medicinal chemistry effort to improve both the metabolic stability and the solubility of 1, resulting in the identification of two analogs achieving over 10-fold increases in plasma exposures in mice. We subsequently showed that one of these analogs (8f, CCG-232601) could inhibit the development of bleomycin-induced dermal fibrosis in mice when administered orally at 50mg/kg, an effect that was comparable to what we had observed earlier with 1 at a 4-fold higher IP dose.
Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury.[Pubmed:24706986]
J Pharmacol Exp Ther. 2014 Jun;349(3):480-6.
Systemic sclerosis (SSc), or scleroderma, similar to many fibrotic disorders, lacks effective therapies. Current trials focus on anti-inflammatory drugs or targeted approaches aimed at one of the many receptor mechanisms initiating fibrosis. In light of evidence that a myocardin-related transcription factor (MRTF)-and serum response factor (SRF)-regulated gene transcriptional program induced by Rho GTPases is essential for myofibroblast activation, we explored the hypothesis that inhibitors of this pathway may represent novel antifibrotics. MRTF/SRF-regulated genes show spontaneously increased expression in primary dermal fibroblasts from patients with diffuse cutaneous SSc. A novel small-molecule inhibitor of MRTF/SRF-regulated transcription (CCG-203971) inhibits expression of connective tissue growth factor (CTGF), alpha-smooth muscle actin (alpha-SMA), and collagen 1 (COL1A2) in both SSc fibroblasts and in lysophosphatidic acid (LPA)-and transforming growth factor beta (TGFbeta)-stimulated fibroblasts. In vivo treatment with CCG-203971 also prevented bleomycin-induced skin thickening and collagen deposition. Thus, targeting the MRTF/SRF gene transcription pathway could provide an efficacious new approach to therapy for SSc and other fibrotic disorders.
Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents.[Pubmed:23707258]
Bioorg Med Chem Lett. 2013 Jul 1;23(13):3826-32.
CCG-1423 (1) is a novel inhibitor of Rho/MKL1/SRF-mediated gene transcription that inhibits invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis. We recently reported the design and synthesis of conformationally restricted analogs (e.g., 2) with improved selectivity for inhibiting invasion versus acute cytotoxicity. In this study we conducted a survey of aromatic substitution with the goal of improving physicochemical parameters (e.g., ClogP, MW) for future efficacy studies in vivo. Two new compounds were identified that attenuated cytotoxicity even further, and were fourfold more potent than 2 at inhibiting PC-3 cell migration in a scratch wound assay. One of these (8a, CCG-203971, IC50=4.2 muM) was well tolerated in mice for 5 days at 100mg/kg/day i.p., and was able to achieve plasma levels exceeding the migration IC50 for up to 3 h.
